EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Laurent Peyrin-Biroulet  ¹     Bruce E. Sands  ²     William Sandborn  ³     Peter D.R. Higgins  ⁴     Fumihito Hirai  ⁵     Vipul Jairath  ⁶     Ruth Belin     Yan Dong     Elisa Gomez Valderas     Debra Miller     Vipin Arora     April Naegeli     Paul Pollack     Jay Tuttle     Toshifumi Hibi    
¹ Nancy University Hospital Inserm U954,Vandoeuvre les Nancy,France
² Icahn School of Medicine at Mount Sinai,New York,United States
³ University of California San Diego,La Jolla,United States
⁴ University of Michigan Health System School of Public Health,Ann Arbor,United States
⁵ Fukuoka University Chikushi Hospital,Chikushino,Japan
⁶ Unive

Session
IBD (Posters)

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)